Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
VRTX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $130.58B
- P/E (TTM)
- 33.14
- Forward P/E
- 25.86
- EPS (TTM)
- $15.54
- Dividend yield
- None
- 52-week range
- 412.27 – 568.67
- Day range
- 513.80 – 531.37
- Volume / Avg
- 1.77M / 1.25M
- Beta
- —
- Shares outstanding
- 253.54M
52-week range
VRTX stock today
Shares of Vertex Pharmaceuticals (VRTX) finished lower on Nov 20 at $515.02, a drop of 1.08% or $5.64 per share, versus the S&P 500's 3.70% decline. At this level, VRTX sits in the middle of its 52-week range of $412.27 to $568.67: 9.4% below the high, set on Nov 2, 2026 and 24.9% above the low. VRTX is up 13.6% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 20.7%.
At 33.1x trailing earnings, Vertex Pharmaceuticals trades above the peer-group median of 20.4x. Its forward P/E of 25.9x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Vertex Pharmaceuticals
Company profileVertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Reshma Kewalramani FASN, M.D.
- Headquarters
- Boston, MA
- Employees
- 6,400
- IPO year
- 1991
- Website
- vrtx.com
Financial highlights
Full financialsIn fiscal 2025, Vertex Pharmaceuticals generated $12.00 billion in revenue, up 8.9% from fiscal 2024, its 11th consecutive year of revenue growth. Net income was $3.95 billion, for a net margin of 32.9% versus a median of 36.7% in the prior 5 years. Gross margin was 86.2% (up from 86.1%) and operating margin 34.8%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $12.00B | $11.02B | $9.87B | $8.93B | $7.57B |
| Growth | +8.90% | +11.66% | +10.51% | +17.91% | +22.06% |
| Net income | $3.95B | $-535.60M | $3.62B | $3.32B | $2.34B |
| EPS (diluted) | $15.32 | $-2.08 | $13.89 | $12.82 | $9.01 |
Analyst forecast
ForecastConsensus (32 analysts)
buy
Avg. price target
$595.36+15.60%
- Strong buy 6
- Buy 20
- Hold 5
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 2, 2026
- EPS actual vs est.
- $4.22 vs $4.36
- Surprise
- -3.21%
VRTX news
All VRTX news- Vertex Pharmaceuticals: Look For Povetacicept Approval In 2 Weeks As Next CatalystSeeking Alpha
- 2 Growth Stocks to Buy in November Without Any HesitationNasdaqVRTX, REGN
- Notable ETF Inflow Detected - QLD, WMT, VRTX, BKNGNasdaqQLD, WMT, VRTX, BKNG
- Genomics Ltd. Announces Extension of Strategic Drug Discovery Collaboration with Vertex PharmaceuticalsPR Newswire
- Johnson & Johnson vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?NasdaqJNJ, VRTX
- Vertex Pharmaceuticals Eyes Nov. 30 Kidney Drug Decision as 2027 Pipeline Milestones LoomNasdaq
- Vertex Pharmaceuticals Incorporated (VRTX) Presents at Jefferies Global Healthcare Conference 2026 TranscriptSeeking Alpha
- Vertex Pharmaceuticals Incorporated (VRTX) Presents at UBS Global Biopharma Conference 2026 TranscriptSeeking Alpha
Vertex Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BMYBristol-Myers Squibb Company | 58.80 | +0.79% | $120.19B | vs VRTX |
| SNYSanofi ADS | 46.52 | +1.00% | $111.70B | vs VRTX |
| PFEPfizer Inc. | 27.40 | -0.51% | $156.18B | vs VRTX |
| NVONovo Nordisk A/S | 37.82 | -2.70% | $166.69B | vs VRTX |
| GSKGSK plc ADR | 47.76 | -0.13% | $95.73B | vs VRTX |
| REGNRegeneron Pharmaceuticals Inc. | 920.69 | -0.19% | $95.24B | vs VRTX |
| ABTAbbott Laboratories | 103.00 | -0.84% | $178.39B | vs VRTX |
| TAKTakeda Pharmaceutical Company Limited ADR | 21.77 | +1.68% | $69.55B | vs VRTX |
Indexes, lists and sector
Index membership
Vertex Pharmaceuticals stock FAQ
What is Vertex Pharmaceuticals's stock price today?
VRTX last traded at $515.02 as of Nov 20, 4:00 PM EST, down 1.08% on the day. Prices are delayed at least 15 minutes.
Does Vertex Pharmaceuticals pay a dividend?
No. Vertex Pharmaceuticals does not currently pay a regular cash dividend.
What is VRTX's P/E ratio?
VRTX trades at a trailing P/E ratio of 33.14 and a forward P/E of 25.86, compared with a median of 20.4 for its closest peers.
Is Vertex Pharmaceuticals in the S&P 500?
Yes. Vertex Pharmaceuticals (VRTX) is a constituent of the S&P 500 index.
Who is Vertex Pharmaceuticals's CEO?
Dr. Reshma Kewalramani FASN, M.D. is the chief executive officer of Vertex Pharmaceuticals Incorporated, which has about 6,400 employees.
Has VRTX ever split its stock?
Yes. The most recent VRTX stock split was a 2-for-1 split on Aug 24, 2000.
What is the VRTX 52-week high?
The 52-week high for VRTX is $568.67 and the 52-week low is $412.27. The stock is currently 9.4% below its high.